atepeq/tico19 huggingface dataset:
Specifically, the virus was found to be detectable for one day on cardboard, for up to three days on plastic (polypropylene) and stainless steel (AISI 304), and for up to four hours on 99% copper.
ብንጹር ቫይረስ ኣብ ካርቶን ኣብ ሓደ ማዓልቲ ተለልዩ፡ኣብ ፕላስቲክን ((polypropylene)) ኣብ መንቅብ ዘይብሉ ኣቻዮን ን ((AISI 304),) ሰለስተ ማዓልቲ፡ኣብ ነሓሲ ን ኣርባዕተ ሰዓታት 99%ተረኺቡ.
This, however, varies depending on the humidity and temperature.
እንተኾነ እዚ ኣብቲ ጠሊን ሙቐትን ይምርኮስ።
Soap and detergent are also effective if correctly used; soap products degrade the virus' fatty protective layer, deactivating it, as well as freeing them from skin and other surfaces.
ሳሙናን መጽረይቲን (detergent)፡ ብጉቡእ ኣብ እንጥቀመሎም እዋን ኣዝዮም ውጽኢታውያን ኢዮም፡ ውጽኢት ናይ ሳሙና ነቲ ስብሒ ዘለዎ ሽፋን ናይ ቫይረስ ብቀሊሉ ክኣልይዎ ዝኽእል ሙኻኑ ኢዩ፡ በዚ ድማ ወይ ካብ ኣእዳው ብቀሊሉ ይኣልይዎም ወይ ድማ ይቀትልዎም።
Other solutions, such as benzalkonium chloride and chlorhexidine gluconate (a surgical disinfectant), are less effective.In a Hong Kong study, saliva samples were taken a median of two days after the start of hospitalization.
ካልኦት ሕውስዋሳት፡ ከም ኣብነት፡ benzalkonium chloride and chlorhexidine gluconate (መምከኒ ናይ መጥባሕቲ)፡ ትሑት ዝኾነ ውጽኢት ኣለዎም፡ ኣብ ሆንግ ኮንግ ኣብ ዝተገብረ መጽናዕቲ፡ ናይ ጥፍጣፍ ቅምሶትት ንምምርማር ድሕሪ ናይ ሕሙም ሕክምና ኣገልግሎት ምጅማር ብውሓዲ 2 መዓልታት ወሲዱ።
In five of six patients, the first sample showed the highest viral load, and the sixth patient showed the highest viral load on the second day tested.
ካብቶም ሽዱሽተ ሕሙማት እቶም ሓሙሽተ፡ እቲ ቀዳማይ ቅምሶ ብዝሒ ዘለዎ ቫይረስ ተራእይዎ፡ እቲ ሻዱሻይ ግዳይ/ሕሙም ድማ ኣብቲ ናይ ካልኣይ መዓልቲ መርመራ ዝበዝሐ ቫይረስ ተራእይዎ።
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus, first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan.
ቢድ ናይ ምስትንፋስ ሲንድሮም ኮሮናቫይረስ ክልተ (Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) ኖቨል ከቢድ ናይ ምስትንፋስ ሲንድሮም ኮሮናቫይረስ ኮይኑ፡ ኣብ ዉሃን ካብ ዝተረክቡ ሰለስተ ግዳያት ናይ ኒሞንያ ዝተፈልየ ኢዩ።
All features of the novel SARS-CoV-2 virus occur in related coronaviruses in nature.
ኩሎም ባህርያት ናይ ኖቨል SARS-CoV-2 ኣብ ካልኦት ዓይነት ናይ ኮሮናቫይረስ ይርከቡ ኢዮም።
Outside the human body, the virus is killed by household soap, which bursts its protective bubble.SARS-CoV-2 is closely related to the original SARS-CoV.
ካብ ኣካላት ሰብ ወጻኢ፡ እዚ ቫይረስ በዚ ናይ ገዛ መሳርሒ ክጠፍእ ይኽእል ኢዩ፡ እዚ ድማ ነቲ ምስቲ ቀንዲ SARS-CoV ዝምድና ዘለዎ SARS-CoV-2 መሸፈኒ ብምእላይ ኢዩ ዝትግበር።
The lungs are the organs most affected by COVID-19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in the type II alveolar cells of the lungs.
ሳናቡእ እተን ብ ኮቪድ-19 ክትንከፋ ዝኽእላ ተነቀፍቲ ኣካላት ኮይነን፡ እዚ ድማ እቲ ቫይረስ ነቶም ኣኣንገድቲ ዋህዮታት ብ ኢንዛይም ኣንጎተሲ-ቀያሪ ኢንዛይም 2 (ACE2)፡ እቲ ኣዝዩ ዓብላሊ ኣብ ዓይነት II ኣሎቨር ናይ ሳምቡእ ዋህዮ፡ ጌሩ ስለ ዝቀጻጸሮ ኢዩ።
The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell.
እዚ ቫይረስ ነቲ ፍሉይ ግልይኮፕሮቲን (glycoprotein) "spike" (peplomer) ዝበሃል ባይታ ብምጥቃም፡ ናብ ACE2 ከላገብን ናብቲ ኣኣንጋዲ ዋህዮ ኽኣቱን ይኽእል።
Acute cardiac injury was found in 12% of infected people admitted in hospital in Wuhan, China, and is more frequent in severe disease.
ከቢድ ናይ ልቢ መዱዳእቲ ኣብቶም 12% ናይቶም ዝተለኽፉን ናብ ሕክምና ናይ ዉሃን፣ ቻይና፡ ዝኣተዉን ተራእዩ፡ እዚ ድማ ኣብ ከበድቲ ሕማማት ብብዝሒ ዝረአ ኢዩ።
Rates of cardiovascular symptoms is high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injury may also be related to ACE2 receptors in the heart.
ኣብ ግዜ ምዕባለ ሕማም ብዝርአ ተኣፋፊ ግብረ-መልስን ናይ ስርዓተ-ምክልኻል ምምዝባልን፡ ደረጃ ናይ ልቢ ምልክታት ልዑል እኳ እንተኾነ፡ ንጡፍ ናይ ማዮካርዲያል (myocardial) ጉድኣት ግን ምስ አብ ልቢ ዝርከቡ ACE2 ዝተባህሉ ተቀበልቲ ክተኣሳሰር ይኽእል’ዩ።
ACE2 receptors are highly expressed in the heart and are involved in heart function.
ተቀበልቲ ACE2 ኣብ ልቢ ብብዝሒ ይርከቡ፡ ኣብ ናይ ልቢ ስረሓት ድማ ብብዝሒ ይሳተፉ።
A high incidence of thrombosis (31%) and venous thromboembolism (25%) have been found in ICU patients with COVID-19 infections and may be related to poor prognosis.Autopsies of people who died of COVID-19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung.
ኣብ ህጹጽ ረዲኤት ተዓቊቦም ኣብ ዘለዉ ሕሙማት ኮቪድ-19፡ ልዑል ጽልዋ ርግኣት ደምን(31%) ቨይናዊ ጸቅጥን(25%) ኣብ ክፍሊ ኢመርጀንሲ ወይ (ICU) ከምዘሎ ተረኺቡ፡ እዚ ድማ ምስ ድኹም ዝኾነ ቅድመ-ገምጋም ክተኣሳሰር ይኽእል ኢዩ። ብኮቪድ-19 ተለኺፎም ኣብ ናይ ዝሞቱ ሰባት ሬሳታት አብ ዝተገብረ መርመራ ዝተበተነ ውስጠ-ግርጻናዊ ጉድኣት( DAD)ን ዝነደረ ዛዕጒ ሊምፍ ኣብ ሳምቡእን ከምዝተረኽበ የነጽር።
Although SARS-COV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID-19 have symptoms of systemic hyperinflammation.
ዋላካ SARS-COV-2 ን ACE2-ገላጺ ናይ አፒተልያል ዋህዮ ኣብ መተንፈሲ ትቦ፡ ክጠውዮ ይኽኣል፡ እቶም ከቢድ ናይ ኮቪድ-19 ሕማም ዘለዎም ናይ ስይስተማቲክ ብርቱዕ ናይ ነድሪ ምልክታት ዘለዎም ተሓከምቲ ኢዮም።
In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID-19 patients.
ብፍላይ ድማ፡ ሰበባት ሕማም GM-CSF-ዝዓቆሩ T-cells፡ ምስቲ ምምዳብ ናይ ነድሪ IL-6-መዕቆሪ ሞኖሳይት (monocytes) ከቢድ ናይ ሳንቡእ ሰበባት ሕማምን፡ ምትሕግጋዝ ከምዘርኣዩ ተፈቲሹ።
Lymphocytic infiltrates have also been reported at autopsy.
ዛዕጊ ልይምፕሆክይቲክ (Lymphocytic) ውን ካብ መርመራ ሬሳ ተማሕላሊፉ።
The WHO has published several testing protocols for the disease.
ዓለምለኻዊ ውድብ ጥዕና (WHO) ዝተፈላለየ መርመራ ብዛዕባ ኮሮናቫይረስ ኣብ መንጎ ሰብ መዚ ኣሕቲሙ።
The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR).
እቲ ግቡእ ኣገባባት ናይ መርመራ real-time reverse transcription polymerase chain reaction (rRT-PCR) ኢዩ።
The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.
እቲ መርመራ በቲ ቅምሶ ናይ ጎሮሮ ዓኽታ ካብ መስተንፈሲ ጎሮሮ ብምውሳድ ኢዩ ዝግበር፡ እንተኾነ ናይ ኣፍንጫ ቅምሶ ወይ ጥፍጣፍ ውን ነቲ ቅምሶ ክትክኦ ይኽእል ኢዩ።
Results are generally available within a few hours to two days.
ብሓፈሻ ውጽኢታት ኣብ ውሽጢ ውሑዳት ሳዓታት ክሳብ ክልተ ማዓልትታት ክርከብ ዝከኣል እዩ።
Blood tests can be used, but these require two blood samples taken two weeks apart and the results have little immediate value.
ናይ ደም መርመራ ክጥቀም ይከኣል ኢዩ፡ ናይ ክልተ ሰሙን ርሕቀታት ዘለዎ ናይ ደም ቅምሶ ብምውሳድ መርመራ ክግበር ይከኣል ኢዩ፡ እቲ ውጽኢት ድማ ቁሩብ ማእከላይ ደረጃ ክህልዎ ይኽእል ኢዩ።
Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus.
ቻይናውያን ተመራመርቲ ስነ-ፍልጠት፡ ዓይነት ናይ ኮሮና ቫይረስ ፈልዮም ጀነቲካዊ ኣሰራርዕኡ ከጽንዑ ክኢሎም ኣለዉ፡ እዚ ድማ ኣብ መላእ ዓለም ዝርከባ ላባራቶሪታት ነናተን PCR ዝተባህለ ልበዳ ሕማም ከለሊ ዝኽእል መርመራታት ከማዕብላ የኽእለን።
As of 4 April 2020, antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used.
ክሳብ መጋቢት 4, 2020፡ ናይ ጸረ-ነፍሳት መርመራ (ነቶም ንጡፋት ምልካፋት ክጸልዎም ዝኽእል፡ ከምኡ`ውን ነቶም ቅድሚ ሕጂ ዝተለኽፉ ሰባት) ኣብ ምምዕባል ኔሩ፡ እንተኾነ ክሳብ ሕጂ ብዙሕ ተጠቃምነት ኣይረኸበን ዘሎ።
The Chinese experience with testing has shown the accuracy is only 60 to 70%.
ናይ ቻይና ተመክሮ ኣብ መርመራ ካብ 60 ክሳብ 70% ልክዕነት ኣርእዩ።
The FDA in the United States approved the first point-of-care test on 21 March 2020 for use at the end of that month.Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk.
ናይ ሕቡራት መንግስታት ኣሜሪካ FDA፡ ናይ መጀመርያ ነጥቢ ናይ ክንክን ኣብ 21 መጋቢት 2020 ኣረጋጊጹ። ናይ መሐከሚ መሳርሒታት ካብ ዞንጋንሆስፒታል ናይ ዉሃን ዩኒቨርሲቲ፡ ኣብቲ ናይ አፒዶሞሎጂ ኣገባባትን ክሊኒካዊ መንገድታትን ብምሙርካስ ነቲ ልኹፍ ክፍለጠሉ ዝኽእል ኣገባብ ፈጢሮም ኣለዉ።
Bilateral multilobar ground-glass opacities with a peripheral, asymmetric and posterior distribution are common in early infection.
ክልተኣዊ ጎድኒ ብዙሕ ገልበዳዊ ታሕቲ-መረጼን ብርሃን ጋራድነታት ምስ ወሰናይ፡ ዘይማዕረን ናይ መቀመጫ ዝርግሐ ኣብቲ ፈለማ ረኽሲ ልሙዳት እዮም።
Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.
እቲ ሕማም እናማዕበለ ክኸይድ ከሎ፡ ሓውሲ ዓብላሊ ነድሪ ናይ ሽፋን ቆፎ ኣፍልቢ፡ ዘይንቡር ጽርገት(ምርቃቅ ናይ ክባዊ ቲሹ ምስ ሓውሰ-ግርጻናዊ ምምላእ)ን ብርታዐን ክርአ ይኽእል።
Few data are available about microscopic lesions and the pathophysiology of COVID-19.
ብዛዕባ ናይ ሚክሮስቾፕ ጉድኣት ን ፓቶፊሶሎጂ (pathophysiology) ናይ ኮቪድ-19ን ኣዝዩ ውሑድ ውሑድ ሓበሬታ ኣሎ።
The main pathological findings at autopsy are:
እቲ ቀንዲ ናይ ኣመዓባብላ ሕማም ውጽኣት ኣብ መመርመሪ።
Macroscopy: pleurisy, pericarditis, lung consolidation and pulmonary oedema
ማይክሮስኮፓዊ (Macroscopy) ነድሪ ሽፋን ሰደራ፡ፐሪካርዲቲ (pericarditis)፡ውህደት ናይ ሳምቡእን ሳምቡኣዊ ኦዴማን
Four types of severity of viral pneumonia can be observed:
ኣርባዕተ ዓይነታት ሓደጋታት ናይ ኒሞንያ በዚ ክትንተኑ ይኽእሉ፡
mild pneumonia: pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
ፎኪስ ኒሞንያ፡ ናይ ፑልሞናሪ ኦደና (pulmonary oedema)፡ ኒሞሳይት ሃይፐርፕላሳ (pneumocyte hyperplasia)፡ ዓብይቲ ኒሞሳይት (large atypical pneumocytes)፡ ናይ መዓንጣ ነድሪ ምስ ሊምፎሳይት ምዙራቕ (lymphocytic infiltration) ከምኡ`ውን ዝተባዝሐ ኒክለታይድ ዋህዮ (multinucleated giant) የጠቃልል።
severe pneumonia: diffuse alveolar damage (DAD) with diffuse alveolar exudates.
ከቢድ ኒሞንያ፡ ዝተዘርገሐ ናይ alveolar መጉዳእቲ (DAD) ምስ ዝተዘርገሐ ናይ alveolar አክሱደይት።
DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.
DAD ቀንዲ ጠንቂ ናይ acute respiratory distress syndrome (ARDS)ን ከቢድ hypoxemia ን ኢዩ።
healing pneumonia: organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
ምፍዋስ ኒሞንያ፡ ኩነት ናይ ነዝዒ ኣብ ትንሓጋዊ ጓንጓታትን መንጎ ቋቁራዊ ጸሕጎትን።
Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction
ደም፡ ውሽጠ ሱርደማዊ ምርጋእ (DIC) ልኮሪትሮብላስቲክ (leukoerythroblastic) ግብረ መልሲ ዘርጊሑ
Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene and avoiding touching the eyes, nose or mouth with unwashed hands.
ንምጉዳል ዕድል፡ እዞም ዝስዕቡ መከላኸሊ ስጉምትታት እዮም፡ ካብገዛ ዘይምውጻእ፡ካብ እኩብ ሰባት ምርሓቕ፡ብሳሙናን ማይን ብውሑድ 20 ካልኢት ብተደጋጋሚ ኢድ ምሕጻብ ፡ ጽቡቕ ዝኾነ ናይ ምስትንፋስ ልምዲ ምጥራይ ፡ ዓይኒ፡ኣፍንጫ፡ኣፍ ብዘይተሓጽበ ኢድ ዘይምትንካፍ።
The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.
CDC ኣፍንጫናን ኣፍናን ፡ ክንህንጥስ እንከለና፡ ብ ሶፍት ወይ ጨርቂ ክንሽፍኖ ይመኽረና፡ እንተደኣ እዚ ዘይረኸብና ግን ብ ጉምቦ ኢዳና ጌርና ክንሽፍኖ ኣሎና።
Proper hand hygiene after any cough or sneeze is encouraged.
ጉቡእ ጽሬት ኢድ ድሕሪ ምስዓል ወይ ምዕንጣስ ዝተተባበዐ እዩ።
The CDC has recommended the use of cloth face coverings in public settings, in part to limit transmission by asymptomatic individuals.Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel and cancelling large public gatherings.
ኣብ እኩብ ህዝቢ ኣብ እንህልወሉ እዋን፡ CDC ነቲ ምሉእ ገጽ መሸፈኒ ክንጥቀመሉ ይመክር፡ ነቲ በቶም ኣሲምፕቶቲክ (ምልክት ናይ ሕማም ዘይብሎም ግዳያት ኣመሓላለፍቲ ሕማም) ሰባት ዝመሓላለፍ ውን ከጉድሎ ይኽእል። ናይ ማሕበራዊ ምርሕሕቅ መደባት ነቲ ምርካባት ናይ ዝተለኽፉ ሰባት ብዓቢ ቁጽሪ ቁጽሪ ከጉድሎ ይኽእል፡ እዚ ድማ ብ ምዕጻው ቤት-ትምህርትታትን ናይ ስራሕ ቦታታትን፡ ምሕጻር ጉዕዞን ከምኡውን ዓበይቲ ናይ ህዝቢ ምትእክካባት ክኸውን ይኽእል።
Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.
ናይ ርሕቀት መምርሒታት፡ ሰባት 6 ፊት (1.8 ሜትሮ) ካብ ነንሕድሕዶም ክረሓሓቁ ከም ዘለዎም ይሕብር።
There is no medication known to be effective at preventing COVID-19.As a vaccine is not expected until 2021 at the earliest, a key part of managing COVID-19 is trying to decrease the epidemic peak, known as "flattening the curve".
ኣድማዒ ዝኾነ ፍሉጥ መከላኸሊ ኮቪድ-19 የለን።ከም ክታበት ክሳብ መጀመርያ 2021 ትጽቢት ኣይግበረሉን።እቲ መፍትሕ ክፋል መቆጻጸሪ ኮቪድ-19 ልዕልና ለብዒ ከተጉድሎ ምፍታን እዩ፡ እዚ ኸኣ ``ምዕጻፍ ጸፍሒ`` ይባሃል።
The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing.
CDC ፡ ውልቀሰባት መብዛሕኡ ግዜ ኣእዳዎም ብሳምናን ማይን ክሕጸቡ፡ ብፍላይ ሽንቲቤት ድሕሪ ምኻድ ወይ ኣእዳው ረሲሖም ምስ ዝረኣዩ፡ ቅድሚ ምምጋብ፡ድሕሪ ኣፍንጫ ፊጥ ምባልን ድሕሪ ምስዓል ወይ ምዕንጣስ ብዉሑዱ ን 20 ካልኢታት ክሕጸቡ ይምሕጸን።
It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production.
ነቲ ካብ ኣልኮል ዝተሰርሐ ናይ ኢድ ሳኒታይዘር (60% ኣልኮል) ክትጥቀመሉ ምስ እትደሊ፡ ሳሙናን ማይን ክትረኽበሉ ኣብ ዘይትኽእል እዋን ጥራይ ክኸውን ኣለዎ። ኣብቶም ናይ ኢድ ሳኒታይዘር ክትረኽበሎም ዘይትኽእል ቦታ ምስ ትህሉ ድማ፡ ውድብ ጥዕና ዓለም (WHO) ነዚ ሳኒታይዘር ንምምስራሕ ክልተ መንገድትታት የማኽር።
In these formulations, the antimicrobial activity arises from ethanol or isopropanol.
ኣብዚ ምምስራሕ ጸረ ደቀቕቲ ህዋሳውያን ዝግበር ንጥፈታት ካብ ኢታኖል (ethanol) ወይ ኢዞፕሮፓኖል (isopropanol) ይጅምር።
Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis".
ሃይድሮጅን ፐሮክሳይድ ኣብ ኣልኮል ንዘለዉ ናይ ባክተርያ (Bacteria) ዘርኢ ንምውጋድ ሓጋዚ ኮይኑ ተረኺቡ።
Glycerol is added as a humectant.
ግሌሴሮል ዝተባህለ ዓይነት ኣልኮል፡ ኣብ ምዕቃብ ጠሊ ልዑል ተራ ከም ዘለዎ ሳብስታንስ ተለልዩ አሎ።
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.
ሰባት ብ ሓገዝቲ ክንክን ምሕዱራት እዮም፡ከም ባዓል ፈሳሲ ብዘይመድሃኒት፡ ኦክስጂናዊ ሓገዝን ፡ሓገዝ ካለኦት ቀንዲ ህዋሳትን ክኾኑ ይኽእል።
The CDC recommends that those who suspect they carry the virus wear a simple face mask.
ምሕጽንታ ሲዲሲ ፡ነቶም ጥርጡራት ቫይረስ ተሰኪሞም ከም ልሙድ ናይ ገጽ ማስኬራ ዝገብሩ እዩ።
Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.
ኤክስትራኮርፖራል መሸፈኒ ናይ ኢክሲጅን (Extracorporeal membrane oxygenation (ECMO))፡ ነቲ ጸገም ናይ ምስትንፋስ ንምፍውስ ተፈቲኑ ኢዩ፡ እቲ ጥቕምታቱ ግን ኣዝዩ ትሑት ኢዩ።
Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.
ግላዊ ጽርየትን ጡዑይ ኣሰራርሓ መግብን ናይ ምክልኻል ዓቕሚ ከም ዘመሓይሽ ተማሕጺኑ።
Supportive treatments may be useful in those with mild symptoms at the early stage of infection.The WHO and Chinese National Health Commission have published recommendations for taking care of people who are hospitalised with COVID-19.
ደጋፊ ናይ ሕክምና ክንክን ኣብቶም ፈኪስ ምልክታት ዘለዎም ኣዝዩ ጠቓሚ ኢዩ፡ እዚ ግን ኣብቲ ናይ መጀመርያ ደረጃ ግዚያት ምልካፍ ኢዩ። ውድብ ጥዕና ዓለም (WHO)ን ናይ ቻይና ሃገራዊ ናይ ጥዕና ኮሚሽንን፡ በዚ ሕማም ኮቪድ-19 ንዝተለኽፉ ሰባት ንዝከናኸኑ እንታይ ዓይነት ጥንቃቐ ክገብሩ ከም ዘለዎም ዝነግር ጽሑፍ ኣሕቱም።
Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.
እቶም ኢንተንሲቪስትን ፑልሞኖሎጂስትስን (Intensivists and pulmonologists in) ናይ ሕቡራት መንግስታት ኣሜሪካ ነቲ ካብ ብዙሓት ትካላትን ወኪላትን ዝረኸብዎ ናይ ሕክምና ኣግባባት ናብቲ ናይ ነጻ ምንጪ ሓበሬታ (IBCC) ኣእትዮሞ ኢዮም።
As of April 2020, there is no specific treatment for COVID-19.
ክሳብ ሚያዝያ 2020፡ ዝኾነ ዝተፈልጠ ሕክምና ናይ ኮቪድ-19 የልቦን፡.
For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.
ገለ ሕክምናዊ ሞያተኛታት ዝምሕጸንዎ ፓራስታሞል (acetaminophen) ኣብ ልዕሊ ኢቡፕሮፈን (ibuprofen) ጥቕሚ መጀመርያ መስመር መርኣያታት እዩ።
Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.
ምምሕልላፍ ቫይረስ ንምቕናስ መጠንቀቕታ ናይ ግድን ክውሰድ ኣለዎ።ብፍላይ ከኣ ኣብ ከባቢ ክንክን ጥዕና፡ ኣቀራርባ ኣገባብ ፍሊት ከመንጩ ይኽእል።
For healthcare professionals caring for people with COVID-19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions and airborne precautions.The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic.
ን ናይ ጥዕና ተኸናኸንቲ ሰብ ሞያ ብ ኮቪድ-19 ዝሓመሙ ዝከናኸኑ ማእከል ምቁጽጻር ሕማም (CDC) እዚ ዝስዕብ ይመክር፡ እቲ ሰብ ኣብ ኣየር-ወለድ መልከፍቲ ዘይብሉ ክፍሊ ክፍለ ((AIIR))፡ ከም ተወሳኺ ናይቲ ስሩዕ ቅድመ ጥንቃቐ ናይ ምትንኻፍ ጥንቃቐ፡ ከምኡውን ናይ ኣየር ወለድ ጥንቃቐ ዘጠቃለለ ኢዩ፡፡ ማእከል ምቁጽጻር ሕማማት (CDC) ግላዊ መከላኸሊ መሳርሒ (PPE) ኣብ ግዜ ዓለምለኻዊ ምስፍሕፋሕ ሕማም ንኽጥቀሙ መርሖታት ኣውጺኡ።
The recommended gear is: PPE gown, respirator or facemask, eye protection, and medical gloves.When available, respirators (instead of facemasks) are preferred.
እቲ ቀንዲ ከም መምርሒ ዝምከረሉ፡ግላዊ መከላኸሊ መሳርሒታት ጋውን፡መተንፈሲ ወይ ናይ ገጽ መሸፈኒ፡ዓይኒ መከላኸሊ፡ናይ ሕክምና ጓንቲ፡ እንተተረኺቡ (ኣብ ክንዲ ናይ ገጽ መሸፈኒ) ምዕቡል መስተንፈሲ መሳርሒ ይምረጽ።
N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA).
N95ናይ ምስትንፋስ ማስክን ኢንዱስትርያዊ ቦታታት ክጥቐሙ ቅቡል ኮይኑ፡ ግና FDA ነዚ ማስክ ኣብ ትሕቲ ህጹጽ ኣጠቓቕማ ባዓል ስልጣን (EUA) ክጥቀሙ ኣፍቂዱ።
They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.
ካብ ኣብ ኣየር ዘንሳፍፉ ነገራት ንኽሕልዉ እዮም ተሰሪሖም።ከም ባዓል ዶሮና ግን ኣድማዕነት ኣንጻር ንጹር ስነሂወታዊ ወኪል ንጥቕሚ ኦፍ-ሌበል ውሕስነት የብሉን።
When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
ናይ ኣፍ መሸፈኒ ኣብ ዘይህልወሉ ማእከል ምቁጽጻር ሕማም፡ ምጥቃም ናይ ገጽ መከላኸሊ ከም ናይ መጨረሻ ኣማራጺ ኣብ ገዛ ዝተሰርሑ ማስክ ክንጥቀም ይመክር።
Most cases of COVID-19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.
ዝበዝሑ ኮቪድ-19 ግዳያት ክሳብ ናይ ቨንቲሌተር ሓገዝ ዘሕትት ሓደጋ ናይ ሕማም የብሎምን፡ እንተኮነ ገለ ሚእታዊት ካብ ሕሙማት ነዚ ሓገዝ ይሓቱ።
The type of respiratory support for individuals with COVID-19 related respiratory failure is being actively studied for people in hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.
እቲ ዓይነት ናይ ምስትንፋስ ደገፋት፡ ነቲ ኮቪድ-19 ዘለዎ ውልቀሰብ፡ ኣብቶም ኣብ ሆስፒታል ዘለዉ ተሓከምቲ ብንጡፍ ኢዩ ዝጽናዕ፡ እዚ ድማ ምስ ገለ መረጋገጺታት ናይ ምክልኻላት ከም ብ ልዑል ናይ ኣፍንጫ ምስዛዕ ብ bi-level ኣወንታዊ ናይ ኣየር ጸቅጢ፡ ክኽልከል ይኽእል።
Whether either of these two leads to the same benefit for people who are critically ill is not known.
ነዞም ኣዝዮም ዝሓመሙ፡ ካብዞም ክልተ ገለ ሓገዝ ክህብዎም ዝኽእል እንተ ኮይኖም ዝፍለጥ ነገር የለን።
Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years).
ዉሑዳት ሓካይም ምስ ህላወ ምስፍሕፋሕ መካኒካዊ ነፋሻነት ምጽናሕ ይመርጹ።ምኽንያቱ ጥበብ እቲ ምዝርጋሕ ናይ ኤሮሶል ነገራት፡ምስ ልዑል ዋሕዚ ሻምብቆታት ኣፍንጫ ይግደብ። ጽንኩር ጉዳያት ኣብ ሽማግለታት ልዕሊ ሱሳን ሰማንያን ዕድመ ዘለዉ ልሙድ እዩ።
Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalisation.
ብዙሓት ዝማዕበላ ሃገራት፡ እኹል ዝኾነ ቁጽሪ ናይ ሆስፒታላት የብለንን ምስ ቁጽሪ ናይ ነበርተን ኣተሓሓዚካ ድማ ነቲ ናይ ጥዕና ሲስተም ዓቀን ዓቢ ቁጽሪ ግዳያት ናይ ኮቪድ-19 ኣብ ዝተራእየሉ እዋን፡ ካላእ መሐከሚ ባይታ ክፈጥራ ገዲድወን።
One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.
ሓደ ኣብ ቻይና ዝተገብረ መጽናዕቲ ከምዝሕብሮ፡ 5% ን ህጹጽ ክንክን ከምእተወስዱ፡ 2.3% መካኒካል ሓገዝ ናይ ኣየር ተዋሂቦም፡ ከም ኡውን 1.4% ሞይቶም።
In China, approximately 30% of people in hospital with COVID-19 are eventually admitted to ICU.
ኣብ ቻይና፡ እቶም ዳርጋ 30% ናብ ሆስፒታል ዝኣተዉ ግዳያት ኮቪድ-19 ናይ ICU ወይ ኢመርጀንሲ ሓገዝ ረኺቦም ኢዮም።
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID-19 and oxygenation becomes increasingly difficult.
መካኒካዊ ሓገዝ ምስትንፋስ ኣዝዩ ዝተሓላለኸ ኮይኑ፡ ሓዲሽ ናይ ስርዓት ምስትንፋስ ጸገም (ARDS) ምልክት ብ ኮቪድ-19 ምስ ዝምዕብል ምስትንፋስ ኣዝዩ ሸጋሪ ይኸውን።
Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.
እቶም ናይ ጸቕጢ መቆጻጸሪ ዘለዎም ቨንቲሌተራት (PEEP)፡ ነቲ ናይ ኦክሲጅን ግቡእ ኣጠቃቅማ ኵውስኸሉን ነቲ ልዕለ ተጠቃምነት ድማ፡ ሳምቡእ መታን ከይህሰ ወይ`ውን pneumothorax ከየስዕብ፡ ክጉድል ኣለዎ።
High PEEP may not be available on older ventilators.
ልዑል PEEP ኣብተን ቨንትሌተራ ዘይክህሉ ይኽእል ኢዩ።
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials.
ዓበይቲ መደባት መጽናዕትታት መድሃኒትን ምስራሕ ፡ ኣብ ጥሪ 2020 ተጀሚሮም፡ ብዙሓት ጸረ-ቫይረስ መድሃኒታት ውን ኣብ ናይ ክሊኒካላት ፈተነታት ይርከቡ።
Remdesivir appears to be the most promising.
ረሚድሲቪር (Remdesivir) ካብቲ ኣዝዩ ውጽኢታዊ ኢዩ።
Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing.
ሓድሽ መድሃኒት ንኽምዕብል ክሳብ 2021ዓ.ም. ክጸንሕ ተኽእሎ እኳ እንተሃለወ ፡ካብቲ ዝፍተን ዘሎ መድሃኒታት መብዛሕትኡ አብ ካልእ ጥቅሚ ንኽውዕል ዝተረጋገጸ ወይ ድማ አብ ምዕቡል ፈተነ ዘሎ ኢዩ።
Antiviral medication may be tried in people with severe disease.
ጸረ-ቫይረስ መድሃኒታት ኣብቶም ከቢድ ዝክነ ደረጃ ናይ ሕማም ዘለዎም ክፍተን ይከኣል ኢዩ።
The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened.
ዓለምለኻዊ ውድብ ጥዕና (WHO) ለበዋ ናይ ኣወንታውያን ኣብ ክፋል ፈተና ናይ ኣድማዕነትን ክእለታዊ ኣተሓሕዛን ወሲዱ።ኣብ ጽንኩር ሂወት ሰብ ወይ ብቐጥታ ኣብ ዝተፈወሰሉ FDA ዉሑስ ዝኾነ ግዝያዊ ፍቓድ ንጸማልያ ፕላዝማ ከም ፈተናዊ ክንክን ኣለዎ።
It has not undergone the clinical studies needed to show it is safe and effective for the disease.
ነቲ ሕማም ዉሑስን ኣድማዕን ከምዝኾነ ንኸርኢ ዘይሓለፎ ክልኒካዊ መጽናዕቲ የድሊ።
In February 2020, China launched a mobile app to deal with the disease outbreak.
ኣብ ለካቲቲ 20, 2020፡ ቻይና፡ ነቲ ምስፍሕፋሕ ኣብ ምግታእ ክሕግዝ ዝኽእል ናይ ሞባይል ፐሮግራም ኣዳልያ።
Users are asked to enter their name and ID number.
ተጠቀምቲ ስሞምን ናይ ID ቁጽሮምን ከእትዉ ይሕበሩ።
The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection.
እዚ ናይ ሞባይል ፕሮግራም ነቶም `ናይ ቀረባ ርክባት` በቲ ናይ መከታተሊ ሓበሬታ ብምጥቃም ክረኽቦ ይኽእል፡ እዚ ድማ ነዚ ምስፍሕፋሕ ናይ ሕማም ብምግታእ ናይ ልኹፋት ቁጽሪ ከጉድል ይኽእል።
Every user can also check the status of three other users.
ነፍሲ ወከፍ ተጠቃሚ ን ካልኦት ሰለስተ ተጠቀምቲ ይቖጻጸር።
If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore.
ዓቕሚ ውሕስነት እንተዳኣ ተረኺቡ፡እቲ ወኸሳ ገዛእ ርእስኻ ምውሻብ ጥራይ ኣይኮነን ዝምህጸን፡ ወግዓዊ ንናይ ውሽጢ ጥዕና ውን የነቓቕሕ እዩ።ምምርማር ዓበይቲ ሓበሬታታት ኣብ ሞባይል ቴሌፎን ዳታ፡ገጻዊ ምልላይ ቴክኖሎጂ፡መስመር ቴሌፎን፡ሰብ ዝሰርሖ ብልሕነት፡ዝተለኽፈ ሰብ ንምርካብን ሰባት ኣብ ደቡብ ኮርያ፡ ታይዋን፡ሲንጋፖር፡ዝቕመጡ ንምርካብ ይጠቅም።
In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus.
ኣብ መጋቢት 2020፡ መንግስቲ እስራኤል ነቶም ኮሮናቫይረስ ዘለዎም ስባት ናይ ሞባይል መከታተሊ ሲስተም ፈጢሩ፡ እዚ ድማ ውሕስነት ናይቶም ዘይተለኽፉ ንምርግጋጽ ኢዩ።
The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.
እቲ እገዳታት ነቲ ውሽባ ንምግዳድ ዝተወስደ ኢዩ ኔሩ፡ ከምኡ`ውን ነቶም ምስቶም ዝተለኽፉ ሰባት ርክባት ዝገበሩ`ውን ንምክልኻል።
Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus.
ከምኡ ውን ኣብ መጋቢት 2020 ዲዩች (Deutsche) ቴሌኮም እኩብ ተሌፎን ናይ ቦታ ሓበሬታ ምስ ወኪል ፈደራል መንግስቲ ጀርመንን ትካል ሮበርት ኮች ፡ምስ እዚ'ውን ምእንቲ መጽናዕትን ምክልኻልን ምዝርጋሕ ናይዚ ቫይረስ ተኻፊሉ።
Russia deployed facial recognition technology to detect quarantine breakers.
ሩስያ ነቲ ናይ ገጽ መለለዪ ሲስተም ተክኖሎጂ ፡ ነቶም ናይ ውሸባ ሕጊ ዝጥሕሱ መፍለጢ ወይ መለለዪ ሰሪሓ።
Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".
ጉልዮ ጋሌራ ዝተባህለ ኢጣልያዊ ናይ ጥዕና ኮሚሽነር፡ 40 ሚእታዊት ካብ ሰባት ብሸለልትነት ምንቅስቃስ ይቅጽሉ አለዉ ብምባል ብናይ ቴሌፎን ኦፕሬተራት ከምዝተሓበረ ተዛሪቡ።
German government conducted a 48 hours weekend hackathon with more than 42.000 participants.
መንግስቲ ጀርመን 48 ሰዓታት ቀዳምን ሰምበትን ሃካቶን ምስ ልዕሊ 42,000 ተሳተፍቲ መሪሑ።
Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
ከምኡ ውን ፕረዚደንት ናይ ኢስቶንያ፡ከርስቲ ካፒጁላኢድ (Kersti Kaljulaid) ኣንጻር ዝርግሐ ኮሮናቫይረስ፡ን ፈጠራዊ መፍትሒታት ዓለምለኻዊ ጻውዒት ጸዊዑ።
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment or fear of the infection itself.
ውልቀሰባት ፡ ምውሻባት፡ ናይ ጉዕዞ ምዕጻዋት፡ ናይ ሕክምና መድሃኒታት ሳዕቤናት፡ ዝጠንቁ ጭንቀት ክገብሩ ይኻሉ ኢዮም።
BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
BBC ሮርይ ኦኮኖር ዝተረቑሐ ኣብ ዝተዛረቦ ኣመልኪቱ፡ምውሳኽ ተነጽሎ ናይ ሰብ፡ጽምዋ፡ጥዕናዊ ሻቕሎት፡ጽቕጥን ቁጠባዊ ምንቁልቋልን ኣኣምሮኣዊ ጥዕና ሰብን ሓጎስን ንኽጎድእ ሙሉእ ማዓት እዩ።
The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold.
ናይዚ ሕማም ምዕባለታት ትሑት ኮይኑ ምስ ዉሑድ ወይ ምልክታት ዘይብሉ ምስ ካለኦት ልሙዳት ናይ ላዕለዋይ ስርዓት ምስትንፋስ ሕማማት ከም ባዓል ሳዓል ይመሳሰል።
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover.
ድኹም ጉዳይ ከም ልሙድ፡ኣብ ውሽጢ ክልተ ሰሙን ይሓውዩ እዮም፡ ብርቱዕ ወይ ሓደገኛ ሕማማት ግን ንኽሓውዩ ክሳብ ሽዱሽተ ሰሙን ይወስድ።
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
ጥንስቲ ጋል-ኣንስተይቲ፡ ኣብቲ ሓበሬታ ናይ ምምሕልላፍ ናይ ኮቪድ-19 ንካልኦት ተመሳሰልቲ ቫይረሳትን ብምሙርካስ ከም SARS ን MERSን (ናይ ኮቪድ-19 ጸብጻብ ግን ምሉእ ኣይነበረን)፡ ኣብ ሓደገኛ ኩነታት ክትህሉ ትኽእል ኢያ። ኣብ ገለ ሰባት ኮቪድ-19 ን ሳንቡእ ብምጥቃዕ ግዳይ ኒሞንያ ክገብራ ይኽእል ኢዩ።
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
ብጽኑዕ አብ ዝተጠቅዑ ሰባት፡ ኮቪድ-19 ናብ ጽኑዕ ጸቅጢ ምስትንፋስ ወይ (ARDS) ክምዕብል ይኽእል፡ እዚ ድማ ድኽመት ምስትንፋስ፡ ረኽሳዊ ነውጺ ወይ ድማ ብዝሐ-ኣካላዊ ወይ ብዝሐ-ኦርጋናዊ ድኽመት ከስዕብ ይኽእል።
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
ምስ ኮቪድ-19 ዝተሓሓዙ ሕልኽላኻት ከም ባዓል፡ረኽሲ፡ዘይንቡር ምርጋእ፡ ናይ ልቢ መጉዳእቲ፡ ኩሊት፡ጸላም ከብዲ፡ዝጎድእ እዩ።
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
ካብ ንቡር ወጻኢ ኣሰራርሓ ኩሊት 4% ኣብዚ ጉጅለ ተራእዩ።ካብ ንቡር ወጻኢ ምርጋእ ብፍላይ ፕሮትሮምቢን (prothrombin) ኣብ ዝውስኸሉ ግዜ 6% ኣብዞም ዝተኣመነሎም ኣብ ሕክምና፡ኮቪድ-19 ከምዝጸንሖም ይዝረብ።ኩሊት ዘይንቡር ኣብ ትሰርሓሉ 4% ኣብዚ ጉጅለ ይረኣዩ።
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
ከባቢ 20-30 ሚእታዊት ናይ ብኮቪድ-19 ዝተለኽፉ ሰባት ዝለዓለ ኢንዛይም ጸላም ከብዲ( transaminases) የርእዩ።
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
ብመሰረት ሓደ ዓይነት ጸብጻብ፡ እቲ ገምጋማዊ ቁጽሪ ናይ መዓልታት ካብ ምልክታት ናይ ሕማም ዝጂምረሉ ክሳብ ሞት ዓሰርተ መዓልታት ኮይኑ እቲ ሓሙሽቱ መዓልታት ኣብ ሕክምና ትእለየሉ ክኸውን ይኽእል።
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
እንተኾነ'ግን ሕሙማን ናብ ጽኑዕ መእለዪ ሕሙማን ዝሰጋገሩ ብገምጋም ሸውዓተ ማዓልቲ ዝኸውን ግዜ ኣብ መንጎ ሕክምና ምእታውን ሙማትን ኔርዎም።
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
ኣብ ቀረባ ግዜ ካብ ዝተገብረ መጽናዕቲታት፡ እቲ ማእከላይ ገምጋም ካብቲ ምልክታት ሕማም ዝረኣየሉ እዋን ጀሚሩ ክሳብ እቲ ናይ ሞት ዘሎ ግዜ ኢዩ፡ ካብ 14 ክሳብ 41 መዓልታት ድማ ድማ ይዝርጋሕ።
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
ኣብ መጽናዕቲ ዓለምለኻዊ ወኪል ጥዕና (NHC) ቻይና ደቂ ኣንስትዮ 1.7% ክሞታ ኸለዋ ደቂ ተባዕትዮ ከኣ 2.8% ይሞቱ።
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
ሂስቶፓቶሎጂካል (Histopathological) መርመራታት ናይ ድሕረ መርመራታት ቅምሶትት ከምዘኣይዎ፡ ምብታን ናይ ትቦ መጉዳእቲ ምስ ዋህዮ ኣዊ ፋይብሮሚክሰድ አክሲደይት (fibromyxoid exudates) ኣብ ክልቲኡ ሳንቡእ ተራእዩ።
Viral cytopathic changes were observed in the pneumocytes.
ቫይረሳዊ ሲቶፋቲክ ለውጢ ኣብቲ ኒሞሳይትስ ተራእዩ።
The lung picture resembled acute respiratory distress syndrome (ARDS).
ናይ ሳንቡእ ስእሊ ከም ዘነጽሮ፡ ከቢድ ዲስትረስ ሲንድሮም (resembled acute respiratory distress syndrome (ARDS)) ከም ዘሎ ኢዩ።
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
ብ ሃገራዊ ጥዕና ኮሚሽን ጥዕና ቻይና ከምዝተማሕላለፈ ኣብ ውሽጢ 11.8% ምዉታት፡ናይ ልቢ ጉዱኣትን ልዑል መጠን ናይ ትሮፖኒን (troponin) ወይ ወቕዒ ልቢ ምዃኑ ተረጋጊጹ።
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
ብመንጽር ናይ ሕቡራት ሃገራት ኣብ መጋቢት ዝሃቡዎ ሓበሬታ፡ 89% ካብቶም ኣብ ሕክምና ዝኣተዉ ሕሉፍ ናይ ጥዕና ሽግራት ኣለዎ። ህላውነት ናይ ጥዕና መሳርሒን ማሕበረ ቁጠባዊ ኩነታት ናይቲ ዘለዉዎ ኣከባቢ ድማ ነቲ መጠነ ሞድን ደደብ ሞትን ክጸልዎ ይኽእል።
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
ጸብጻባት ናይ ሞት ኣብ ዝተፈላለየ ኩነታት፡ ኣብቲ ናይ ከባብያዊ ፍልልይ ይሙርኮስ፡ ብዘይካ እዚ ኣብቲ ኣገባባት ዘጋጥም ሽግራት ውን ይምርኮስ ኢዩ።
The under-counting of mild cases can cause the mortality rate to be overestimated.
ነቶም ብዙሕ ምልክታት ዘይብሎም ኣብ ጸብጻብ ናይ ቁጽሪ ብዘይ ምእታው፡ እቲ መጠነ ሞት ልዕሊ-ግምት ክኸውን ይኽእል ኢይ።
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
ሽሕ'ኳ እቲ ሓቂ ውጽኢት ዝሞቱ ሕሉፍ ሕማም ዝጸንሖም እንተኾኑ፡መጠን እዋናዊ መዋትነት ግን ትሑት ግምት ኣለዎ።
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
ኣትከኽቲ ምስ ዘየትክኹ ክወዳደር ከሎ ብ 1.4 ግዜ ተመሳሳሊ ጽንኩር ምልክታት ናይ ኮቪድ19 ኣለዎ። ብገምጋም 2.4 ግዜ ዓቢ ምምስሳል ጽዑቕ ናይ ምክትታል ሓላፍነት ወይ ሞት የኸትል።ምስ ዘየትክኹ ብምንጽጻር እቲ ሕማም ምስኦም ነዊሕ ይጸንሕ።
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
ናይ ሆንግኮንግ ሕክምና በዓል ስልጣን ከም ዝረኸብዎ ካብ 20% ክሳብ 30% ናይ ሳምቡእ ዓቕሚ ኣብ ውሑዳት ሰባት ሓሚሞም ዝሓወዩ ከምዝጎደለን ናይ ሳምቡእ ስካን ኣብ ህዋሳት ዕንወት ከምዘርኣየን ተረኺቡ።
This may also lead to post-intensive care syndrome following recovery.
እዚ'ውን ናብ ድሕረ ጽኑዕ ክትትል ምልክት ድሕሪ ምሕዋይ ከስዕብ ይኽእል።
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
ክሳብ መጋቢት 2020፡ እቶም ቅድሚ ሕጂ ዝተለኽፉን ሓዲሽ መልከፍቲ ናይ ምክልኻል ስርዓቶም ክሳብ ክንደይ ውጽኢታዊ ሙኻኑ ኣይተፈልጠንን።
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
ናይ ምክልኻል ሲስተም፡ ምስቲ ናይ ካልኦት ኮሮናቫይረሳት ባህርያት ይቀያየር፡ እንተኾነ ኩሎም እቶም ካብ ኮቪድ-19 ዝሓወዩ ግዳያት ጸኒሑ ኣብ ዝተገብረ ጸብጻብ ተደጋጋሚ ብ ኣወንታዊ ከም ዝተመረመሩ ተፈሊጡ።
These cases are believed to be worsening of a lingering infection rather than re-infection.
እዞም ግዳያት ነቲ ዝተረፈ ምልካፍ መሊሶም ከግድድዎ ኢዮም ካብቲ ካልኣይ-መልከፍቲ ንላዕሊ።
The virus is thought to be natural and have an animal origin, through spillover infection.
ቫይረስ ባህርያዊ ንኽኸውን፡ናይ እንስሳ መበቆል ዘለዎ እንዳለሓመ ዝኸይድ መልከፍቲ ምዃኑን ተዘሪቡ።
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
እቲ ቀንዲ መበገሲኡ ፍሉጥ እንተዘይኮነ፡ኮይኑ ግን ብ ታሕሳስ-2019 ምስፍሕፋሕ ናይዚ ብከላ ካብ ሰብ ናብ ሰብ ምትሕልላፍ ሙሉእ ብሙሉእ መጺኡ።
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
ኣብቶም ናይ መጀመርታ 41 ጉዳያት መልከፍቲ ኮቪድ-19 ኣብ ዝተገብረ መጽናዕቲ፡ ኣብ “ዘ-ላንሰት” ከምዝተገልጸ፡ እቲ ናይ መጀመርታ ምልክታት ናይዚ ቫይረስ ካብ ዕለት 1 ናይ ወርሒ ታሕሳስ 2019 ጀሚሩ ከምዝተራእየ የነጽር።
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
ወግዓዊ ጸብጻብ ናይ ውድብ ጥዕና ዓለም (WHO) ከም ዝሓበሮ፡ እቲ ዝቀልጠፈ ምዝጉብ ናይ መጀመርያ ምልክታት ዝተራእየሉ ኣብ 8 ታሕሳስ 2019 ኢዩ ኔሩ።
Several measures are commonly used to quantify mortality.
ገለ ገለ ተበግሶታት ነቲ ሞራል መምዘኒ ይጠቕሙ ኢዮም።
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
እዞም ቁጽርታት ብኣከባቢ ወይ ዞባ ይፈላለዩ፡ በቲ መጠን ናይ መርመራ ፡ ፡ ናይ ጥዕና ሲስተም ብቅዓት፡ ኣተሓካክማ ኣገባብ፡ ናይ ምሕካም ኣማራጺታት፡ ካብቲ ናይ መጀመርያ ምስፍሕፋሕ ዝተራእየሉ እዋን ዘሎ ግዚያት፡ ዕድማ፡ ጾታ፡ ከምኡ`ውን ሓፈሻዊ ናይ ጥዕና ዓይነታት ካብቶም ኣዝዮም ጸለውቲ ረቃሒታት ኢዮም።
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
ኣብ መወዳእታ 2019 ፡ዓለምለኻዊ ውድብ ጥዕና (WHO) ነዞም ህጹጽ ሕማም ICD-10 ዘለዎም ኣብ ክፍሊ መርመራ ዝተረጋገጸ ልኽፈት SARS-CoV-2 ንዝሞቱ ኣብ ኮድ U07.1 መዲብዎም።ኣብ ክሊኒካዊ ወይ ስነለበዳዊ ፍወሳ ኮቪድ-19 ብዘይ ናይ ክፍለ መርመራ ርጉጽነት ልኽፈት SARS-CoV-2 ንዝሞቱ ኣብ ኮድ U07.2 መዲብዎም።ሬሾ ሞትን መልከፍትን፡ቁጽሪ ዝሞቱ ክምቀል ን ዝተለኽፉ ምስ ዝተዋህበ ግዜ ከምዝኾነ የንጸባርቕ።
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
ኣብቲ ናይ ጆን ሆፕኪንስ ዩኒቨርሲቲ ጸብጻብ ብምሙርካስ፡ ዓለማዊ መጠነ ሞት ምስ ቁጽሪ ግዳያት ክነጻጸር እንከሎ 6.9% (153,822/2,240,191) ኢዩ፡ እዚ ጸብጻብ ክሳብ 17 ሚያዝያ 2020 ዝትገብረ ኢዩ።
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
እዚ ቁጽሪ እዚ ብ ዞባ ይፈላለ። ካልኦት ስገምትታት ነዞም ዝስዕቡ የጠቃልል፡ ናይ ሞት መጠን (CFR)፡ ነቲ ብሕማም ዝሞተ ክሳብ ክንደይ ናይ ሕክምና ኣገልግሎት ብ ሚእታዊት ከም ዝረኸቡ ፡ ከምኡውን ነቲ ምምሕልላፍ ናይ መጠነ ሞት (IFR)፡ እዚ ድማ ሚእታዊት ናይ ዝተለኽፈ ውልቀሰብ (ዝተሓከመን ዘይተሓከመን) ከምኡውን ብሰንኩ ዝሞቱ ዝሓቆፈ ኢዩ።
These statistics are not time bound and follow a specific population from infection through case resolution.
እዞም ዝርዝራት ብ ቁጽሪ ዝድረቱ ኣይከኑን፡ ካብቲ ምልካፍ ክሳብ ምፍታሕ ሽግራት ኣብ ዘሎ ጉዳያት ድማ ጸብጻብ ይገብሩ።
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
ዋላ`ካ ኩሎም ዝተለኽፉ ሰባት ጸረ-ቫይረስ ኣየማዕብሉ፡ ህላውነት ናይ ጸረ-ቫይረስ ክንደይ ሰባት ከም ዝተለኽፉ ሓበሬታ ክህበና ይኽእል ኢዩ።
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
ኣብ ማእከል ናይቲ ምስፍሕፋሕ ናይ ጥልያን፡ ኣብ ጥልያን ካብ ዝርከባ ነኣሽቱ ዓድታት ካስቲሎጃ ጅ ዳዳ (Castiglione d'Adda)፡ 4600፡ 80 (1.7%) ብሰንኪ እዚ ቫይረስ ሞይቶም።
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
ውሽጣዊ ምምሕልላፍ ሕማም ኣብ ዝበዝሓ ሃገራትን ኣብ ሽዱሽቲኤን ዓለምለኻዊ ውድብ ጥዕና ዞባታትን ተመዝጊቡ።ኣብ ጋንገልት እቲ ሕማም ብ ምርኢት ናይ ጽምብላት ናብ መንእሰያት ተዘርጊሑ። ብተዛማዲ ዉሑድ ዓቐን ሞት ኣምጺኡ። ግን ከኣ ብ ኮቪድ-19 ከምዝሞቱ ወግዓዊ ክምደቡ ኣይከኣሉን።
Furthermore, the German health system has not been overwhelmed.
ካብዚ ሓሊፉ ናይ ጀርመን ጥዕናዊ ስርዓት ዓብላሊ ኣይጸንሐን።
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
ኣብ ነዘርላንድ፡ ካብ ወሃብቲ ደም ካብ ዝተገብረ ዳህሳስ 3% ጸረ-ነፍሳት ክህልዎም ይኽእል ኢዩ።
69 (0.004% of the population) have been confirmed to have died from COVID-19.
69 (0.004% ናይ ህዝቢ)፡ ብ ኮቪድ-19 ሞይቶም ክኾኑ ከም ዝኽእሉ ተገሚቱ።
The impact of the pandemic and its mortality rate are different for men and women.
ጽልዋ ናይዚ ተላባዒን መጠን ሞት ደቒ ተባዕትዮን ደቂ ኣንስትዮን ዝተፈላለየ እዩ።
Mortality is higher in men in studies conducted in China and Italy.
ኣብ ቻይናን ጥልያንን፡ ኣብ ዝተገብሩ መጽናዕትታት መጠነ ሞት ካብ ኣወዳት ንላዕሊ ኣብ ኣዋልድ ይውሕድ።
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
እቲ ዝዓበየ ሓደጋ ን ደቂ-ተባዕትዮ ኣብ 50ታት ኢዩ፡ እቲ ፍልልይ ኣብ መንጎ ደቂ-ተባዕትዮን ደቂ-ኣንስትዮን ኣብ 90ታት ዝተቀራረበ ኢዩ።
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
ኣብ ቻይና፡ መጠን ሞት ኣብ ደቂ ተባዕትዮ 2.8 ሚእታዊት፡ አብ ደቂ ኣንስትዮ ድማ 1.7 ሚእታዊት ኢዩ።
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
እቲ ልክዕ ምኽንያት ናይዚ ሽዱሽተ ፍልልያት ኣይተፈልጠን፡ እንተኾነ ጀነቲካዊን ባህርያውን ለቃሒታት ክኾኑ ይኽእሉ።
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
ኣብ ጾታ ዝምርኮስ ናይ ምክልኻል ኣካላት ፍልልይ፡ እቲ ውሑድ ተጠቃምነት ናይ ሽጋራ ኣብ ደቂ-ኣንስትዮን ደቂ-ተባዕትዮን፡ ነቲ co-morbid ዘማዕበሉ (ከም ጸቕጢ ኣብ ንኡስ ዕድማናይ ደቂ-ተባትዕዮ ካብ ናይ ደቂኣንስትዮ)፡ ዝበዝሐ ናይ ሞት ሓደጋ ኣብ ደቂ-ተባትዕዮ ኣስዒቡ።
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
ኣብ ኤውሮጳ፡ 57% ካብቶም ዝተለኽፉ ውልቀሰባት ደቂ-ተባዕትዮ ኢዮም ፡ ካብቶም ብ ኮቪድ-19 ዝሞቱ ድማ እተን 72% ደቂ-ኣንስትዮ ኢየን ኔረን ።
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
ኣብ ሚያዝያ 2020, መንግስቲ ሕቡራት መንግስትታት ምስ ናይ መልከፍቲ ኮቪድ-19 ዝተሓሓዝ ምልክት ጾታዊ-ርክብ ሓበሬታ ኣይረኸበን።
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
ቫይረሳዊ ሕማም ከም ባዓል ኢቦላ (Ebola)፡ HIV ፡ ሳዓል፡ SARS ን ደቂ ተባዕትዮን ደቂ ኣንስትዮን ብዝተፈላለየ መንገዲ ከምዝጸልዎም መጽናዕትታት የርእዮ።
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
ዝለዓለ ሚእታዊት ናይ ጥዕና ደቂ ኣንስትዮ ሰራሕተኛታት ብፍላይ ነርሳት ብ ቫይረስ ዝተቓልዓ እየን።
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
ውድብ ጥዕና ዓለም (WHO) ኣብ 11 ለካቲት 2020 ፡ ወግዓዊ ስም ናይዚ ሕማም ``ኮቪድ-19`` ከም ዝበሃል ኣዊጁ።
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
መራሒ ውድብ ጥዕና ዓለም (WHO)፡ ኣድሓኖም ገብረየሱስ፡ CO ነቲ ኮሮና ዝበሃል ቫይረስ ከም ዝውክል ገሊጹ፡ 19 ድማ እቲ ምስፍሕፋሕ መዓስ ከም ዝጀመረ ይነግር፡ 31 ታሕሳስ 2019።
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
እዚ ስም እዚ ነቲ ፍሉይ ጀኦግራፍያዊ ቦታ ከም መወከሲ ክይጥቅም (ቻይና ከም ኣብነት)፡ ናይ እንስሳ ዓሌት ወይ እኩባት ሰባት፡ እዚ ድማ ምስቲ ዓለምለኻዊ ሕጊ ካብ ምውራድ/ዓሌትነት ናይዞም ዝተጠቕሱ ዓሌት ሰባት ወይ ቦታታት ዝተመርኮሰ ኢዩ። እዚ ነዚ ኮቪድ-19 ዝበሃል ሕማም ዘስዕብ ቫይረስ severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ይበሃል።
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
ውድብ ጥዕና ዓለም (WHO) ኣብ ህዝባዊ ርክባት ዝጥቀመሉ ኣጸዋውዓ ኮቪድ-19 ወይ ድማ ንኮቪድ-19 ዘስዓበ ቫይረስ ዝብል ኢዩ።
Both the disease and virus are commonly referred to as "coronavirus".
ክልቲኦም እቲ ሕማምን ቫይረስን ``ኮሮናቫይረስ`` ተባሂሎም ይጽውዑ።
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
ኣብቲ ናይ መጀመርያ ምስፍሕፋሕ ኣብ ዉሃን ቻይና፡ እቲ ቫይረስ ``ኮሮናቫይረስ`` እቲ ሕማም ድማ ``ዉሃን ኮሮናቫይረስ`` ተባሂሎም ይፍለጡ ኔሮም።
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
ኣብ ጥሪ 2020፡ ዓለምለኻዊ ውድብ ጥዕና ክልቲኡ 2019-nCov ን 2019-nCoV ን ከቢድመተሓላለፊ ናይ ምስትንፋስ ሕማምን፡ ከም ግዝያዊ ኣስማት ናይዞም ዝተጠቅሱ ዓይነት ቫይረስን ሕማምን ክኸውን፡ ብመሰረት መምርሒ 2015 ኣንጻር ምጥቃም ናይ ሕማም ቦታታትን ኣስማትን ምሕጽንታ ሂቡ።
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
ናይ ኮቪድ-19 ን SARS-CoV-2 ወግዓዊ ኣስማት ብ ለካቲት 11,2020 ተዋሂቡ።
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
ብሰንኪ ግቡእ ናይ ጠለባት ምምላእ ዘይምህላዉ፡ ገለ ዲጂታላዊ መሳርሒ ዝጥቀማ ትካላት ናይ ጥዕና ክንክን መሳርሒ ከም ናይ ኣፍንጫ መጽረዪን ናይ ቨንቲለተር ክፋላትን ይሓትማ ኣለዋ።
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
ኣብ ሓንቲ ኣብነት፡ ናይ ኢጣልያ ሆስፒታል ሃንደበት ቨንትሌቶር ምስደለዩ፡ እቲ ኣፍራዪ ድማ ኣብ ግቡእ ግዜ ከብጽሖ ስለዘይከኣለ፡ ኣብቲ ከባቢ ዝነበረ መመስርሒ ክሳብ 100 ሓባ ዝኣክል ትቦታት ናይ ቨንትሌተራት ኣብ ውሽጢ ሓደ ምሸት ከፍሪ ክኢሉ።
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
ኮቪድ-19 ድሕሪ ምብጋሱ፡ ብዙሕ ናይ ተንኮል ክልሰ-ሓሳባት፡ ጌጋን ሓቀኛ ዘይኮነን ሓበሬታ ብዛዕባ መበቆል፡መጠን፡ ምክልኻል፡ ክንክንን ካልእ ገጻት ናይዚ ሕማምን ተቀላቂሉን ብቅልጡፍ ኣስፋሕፊሑን።
Humans appear to be capable of spreading the virus to some other animals.
ደቂ ሰባት ነዚ ቫይረስ ናብ ካልኦት እንስሳታት ናይ ምምሕልላፍ ብቅዓት ወይ ዓቅሚ ኣለዎም።
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
እቲ መጽናዕቲ ምብዛሕ ናይ ቫይረስ ኣብ ሓሰማታት፡ ማይ-ደርሆታት ከምኡውን ደርሆ ፡ ከምዘየርኣየ ሓቢሩ።
No medications or vaccine is approved to treat the disease.
ነዚ ሕማም ንምፍዋስ ዝጸደቐ ፍወሳ ወይ ክታበት የለን።
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
ዓለምለኻዊ መጽናዕቲ ኣብ ክታበታትን መድሃኒታትን ናይ ኮቪድ-19 ብ ናይ መንግስቲ ማሕበራት፡ ናይ ትምህርቲ ትካላት ከምኡ`ውን ናይ ዓበይቲ ትካላት ናይ መጽናዕቲ ጉጅለታት፡ ዝግበር ዘሎ ይቕጽል ኣሎ።
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
ኣብ መጋቢት፡ ውድብ ጥዕና ዓለም (WHO) ነቲ ናይ ``ሓድነት ፈተነ`` ጀሚርዎ፡ እዚ ድማ ነቶም ዝተራእዩ ኣርባዕተ ዓይነት ጸረ-ቫይረሳት መሐከሚ ኢዩ፡ ዕላማኡ ውን ውጽኢታውነት ንምውሳኽ ኢዩ።
There is no available vaccine, but various agencies are actively developing vaccine candidates.
ክሳብ ሕጂ ርጉጽ ዝኾነ ክታበት የሎን፡ እንተኮነ ብዙሓት ትካላት ናይ ክታበት ፍርያት ውድድራት ይገብራ ኣለዋ።
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
ናይ ቅድም ስራሕ ናይ SARS-CoV ኣብ ትግባረ ውዒሉ፡ምኽንያቱ ክልቲኦም SARS-CoV ሳርስ SARS-CoV-2 ን ናብ ናይ ወዲ ሰብ ዋሃዮ ንምእታው ACE2 ስለዝጥቀሙ።
There are three vaccination strategies being investigated.
ሰለስተ ዝተመርመሩ ናይ ክታበት ኣገባባት ኣለዉ።
First, researchers aim to build a whole virus vaccine.
ብመጀመርያ ተመራመርቲ ናይ ሙሉእ ኮሮና-ቫይረስ ክታበት ንምስራሕ ዓሊሞም።
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
ጥቅሚ ናይዚ ቫይረስ፡ ዝሞተ ወይ ድማ ዘይሰርሕ ክኸውን ይኽእል፡ ኣብ ግዜ ሓዲሽ መልከፍቲ ኮቪድ-19 ን ኣካላት ወዲ ሰብ ቅልጡፍ ዝኾነ ናይ ምክልኻል ስጉምቲ ንዅአስድ ይሕፍዞ።
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
እቲ ካልኣይ መደብ፡ ንኡስ-ክፋል ናይ ክታበት፡ ነቲ ክታበት ኣብ ምፍጣር ዝዕለመ ኮይኑ፡ ነቲ ናይ ምክልኻል ዓቅሚ ድማ ክሳብ ገለ ደረጃ ናይ ምክልኻል ብቅዓት ን ቫይረስ ኸርኢ ኣለዎ።
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
ኣብ ጉዳይ SARS-CoV-2፡ እዚ መጽናዕቲ ኣብ ለዕሊ ፕሮቲን ዝጸቐጠ እዩ።እዚ ከኣ ነቲ ቫይረስ ግሂሱ ንተቐባሊ ምራቕ ACE2 ይሕግዝ።
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
እቲ ሳልሳይ ስትራቴጂ ናይ ኣሲድ ሕመረት-ዋሃዮ ክታበት DNA ወይ RNA ክታበት፡እቲ ቀንዲ ናይ ክታበት ናይ መፍጠሪ መገዲ)።
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
ብ ምርምር ዝተሰርሑ ክታበታት፡ ን ውጽኢታውነት ናይ ደረጃ ብቕዓትን ብግቡእ ክምርመሩ ኣለዎም። ኣብ መጋቢት 16, 2020፡ ናይ መጀመርያ ናይ ክሊኒክ ክታበት ብ ኣርባዕተ ወለንተኛታት ኣብ ሲያትል ተጀሚሩ።
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
ክታበት ዘይጓዳእ ጀነቲካዊ ስርዓት ዝዕቅብ እዩ፡ ካብ ቫይረስ ዝተዳቐለ ግን ጠንቁ ሕማም እዩ። ጸረ ኣካል ጽግዕተኛዊ ዕዙዝነት ስለዘለዎ ን ክታበታዊ ምዕባለ ኣብ SARS-COV-2ዝብድህ ዓቕሚ ከምዘለዎ ኣመልኪቱ፡እዚ ግን ኣካራኻሪ እዩ።
There are more than 300 active clinical trials underway as of April 2020.
ክሳብ መጋቢት 2020 ኣብ ዘሎ ግዜ፡ ክሳብ 300 ዝበዝሑ ናይ ክሊኒክ ፈተነታት ተኻይዶም ኣለዉ።
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
ሸውዓተ ፈተነታት ናይ ዓሶ ምፍዋስ መድሃኒታት ቅድሚ ሕጂ መረጋገጺ ወረቀት ረኺቦም ኢዮም፡ ካብ ኣቶም ድማ እቶም ኣርባዕተ ክሎሮኪንን ሃይድሮ ክሎሮኪንን (chloroquine and hydroxychloroquine) ዝተመርኮሱ ኢዮም።
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
ዝበዝሕ ናይ ጸረ ቫይራል መድሃኒታት፡ ቻይና መጽናዕቲ ናይ ዳግመ ምደባ ጌሮሙሉ። ትሽዓተ ገጻት 111 ፈተነታት ረመደሰቪር (remdesivir) ዝተፈላለያ ሃገራት ብምሕላፍ ምኽንያት ምምሕልላፍ ጸብጻብ ኣብ መወዳእታ ሚያዝያ እዩ።
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
ዝተዓጻጸፍ ትንታነ ናይ ኮቪድ-19 ክሊኒካዊ ምዕባለ ክታበትን ናይ መድሃኒት ምምዕባልን ክሳብ ሚያዝያ 2020 ኣብ ዘሎ ግዜ ይቕጽል ኣሎ። ብዙሓት ዝጸንሑ ናይ ጸረ ቫይረስ መድሃኒታት ን ኮቪድ-19 ሕክምና ይምርመሩ ኣለዉ፡ እዚ ድማ ነዞም ዝስዕቡ የጠቃልል፡ ረሚድሲቪር (remdesivir), ክሎሮኪንን ሃይድሮ ክሎሮኪንን (chloroquine and hydroxychloroquine)፡ ላፒኖቪር/ሪቶኖቪር ( lopinavir/ritonavir) ከምኡውን ሪቶኖቪር/ላፒኖቪር (lopinavir/ritonavir)፡ ምስ ጣልቃ-ኣታዊ ቤታ (Beta) ብምሕዋስ።
There is tentative evidence for efficacy by remdesivir, as of March 2020.
ኣብ መጋቢት 2020 ግዝያዊ መረጋገጺ ኣድማዒ ውጽኢት ብ ሪምደሲቪር (remdesivir)ተዋሂቡ።
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
ብ ረምደሲቪር (remdesivir) ብምጥቃም ካብ ዝተሓከሙ ናይ ክንሊኒክ ምምሕያሻት ክገብሩ ተራእዮም።
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
ሳልሳይ ደረጃ ሕክምናዊ ፈተነ ኣብ ሕቡራት መንግስትታት ፡ቻይና ፡ጥልያን፡ እንዳተተግበረ እዩ። ኣብ ቻይና ኣብ ለካቲት 2020 ክሎሮኪን ኣቐዲሙ ናይ ዓሶ፡ መድሃኒት ዝነበረ ናይ መጀመርያ ውጽኢት ሒዙ ተጸኒዑ።
However, there are calls for peer review of the research.
እንተኾነ፡ ናይቶም መጽናዕታት ምርግጋጽ ክግበር ጻውዒት ይግበር ኣሎ።
Korean and Chinese Health Authorities recommend the use of chloroquine.
ኮርያን ቻይናን ናይ ጥዕና ባዓል ስልጣናት ክሎሮኲዩን (chloroquine) ክጥቀሙ መኺሮም።
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
እንተኾነ ግን ፡ውሃን ትካል ናይ ቪሮሎጂይ መዓልታዊ ዓቐን ናይ መድሃኒት ሓደ ግራም ክኸውን ተማሕጺኖም፡ ክልተ ዕጽፊ ናይቲ ዓቐን ብጣዕሚ ሓደገኛን ቀታልን ክኸውን ከምዝኽእል ኣዘኻኺሮም።
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
ኣብ 28 መጋቢት 2020፡ናይ FDA ህጹጽ ሓገዝ ፍቓድ ን ሃይድሮክሲክሎሮኪንን (hydroxychloroquine) ክሎሮኪንን (chloroquine) ኣብ ድርሳን ሓካይም ነቲ ናይ ኮቪድ-19 ክንክን ጥዕና ሰባት መከላኸሊ፡ሪባቪሪን (ribavirin) ፡ ወይ ኡሚፈኖቪር (umifenovir) ንጥቕሚ ኣንጻር ኮቪድ-19፡ ቻይና 7ይ ሕታም ሓፈሻዊ መምርሒ ኣሕቲማ።
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
ናይ መጀመርያ ሓበሬታ ከም ዘመልክቶ ልዑል ዓቐን መድሃኒት ናይ ሪባቪሪን (ribavirin) ንሕፍረት ሳርስ SARS-CoV-2 ኣብ ቪትሮ ኣገዳሲ እዩ።
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
ኖቲክዞሳንደ (Nitazoxanide)፡ ህይወታውያን (VIVO) ትሑት ምክልኻል ናይ SARS-CoV-2 ኣብ ዘርእይሉ እዋን፡ ክንጥቀመሉ ይመኽሩ። መጽናዕቲ ከም ዝሕብርዎ እቲ ናይ መጀመርያ ናይ ስፓይክ ፕሮቲን (spike protein)፡ ብ ፕሮቲስ ሰሪነ ክልተ (protease serine 2 (TMPRSS2)) ዝተሰርሐ፡ ነቲ ምእታው ናይ SARS-CoV-2 ብ ምትእትታው ናይ ACE2 ተቀባሊ፡ ኣዝዩ ኣገዳሲ ኢዩ።
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
መጽናዕትታት ናይ ክሎሮኮንን ሃይድሮክሎሮኢንን (chloroquine and hydroxychloroquine) ብ azithromycinንን ብዘይ ብኡን፡ነቲ ናይ ሕክምን ስድራ-ቤት ካብዚ ክንክን ናይ ሕክምና ክኽልክሎም ዘኽእል ዓበይቲ ሓጹራት ኣለዎ፡ እዚ ግን ብዘይ ዓሚቕ መጽናዕቲ ዝተገብረ ገምጋም ኢዩ። Oseltamivir ን SARS-CoV-2ኣብ ቪትሮ (vitro) ክኽልክሎ ኣይክእልን ኢዩ፡ ኣብ ሕክምና ናይ ኮቪድ-19 ድማ ዝኾነ ተራ የብሉን።
Cytokine storm can be a complication in the later stages of severe COVID-19.
ሲቶኪንስ (Cytokine) ስቶርም ካብቶም ኣብ ዝኸፈአ ደረጃ ናይ ኮቪድ-19 ዝኽሰት ሳዕቤን እዩ።
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
ሃይድሮክሲ-ክሎሮኪን ጸረ ሳይቶኪን ዝኾኑ ማዕበላዊ ጠባያት ክህልዎ ከምዝኽእል ዘረድእ መርትዖ ኣሎ። ሃገራዊ ኮሚሽን ጥዕና ቻይና ቶሲሊዙማብ ንዝተባህለ መድሃኒት ኣብ ናይ ክንክን ቅርጽታት ኣእትይዎ ኣሎ።
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
ድሕሪ ኣብቶም ከበድቲ ሕማማት ዘለዎም ሰባት ዝተገብረ ፈተነ ውጽኢታውነት ምሃቡ፡ ገጽ 2 ሓፈሻዊ መርመራታትታ ኣብ ኢጣልያ ብ ሃገራዊ ደረጃ ክትግበር ይትግበር ኣሎ።
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
ምስ ናይ ቅምሶ ደም ናይ ፈሪቲን (serum ferritin blood) ዝተሓወሰ መርመራ ነቲ ናይ ሲይቶኪን ነድሪ (cytokine storms) ንምልላይ፡ ነቲ ተራኽቦታትን ምዕባለታትን ንምክልኻል፡ ኣብ ገለ ዝተለኽፉ ሰባት ጠንቂ ናይ ሞት ኮይኖም ዝሕሰቡ ኢዮም።
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
ናይ interleukin-6 ተቃዋሚ ተቀባሊ፡ ብ FDA ተረጋጊጹ፡ እዚ ድማ ብ ናይ ኣብ ረትሮሰፕቲቭ (retrospective) ናይ ግዳያት መጽናዕቲ ን ሕክምና ናይ ስተሮይድ ረፍራክቶሪ ሲይቶኪን (steroid refractory cytokine) ዝነስዖ ሲንድሮም (ብ ዝተፈላለየ ጠንቅታት CAR T ዋህዮሕክምና)፡ ኣብ 2017 ብዝተገብረ መጽናዕቲ ኢዩ።
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
ክሳብ ሕጂ፡ቶሲሊዙማብ ን ሲኣሬስ ኣፍማዒ ፍወሳ (CRS) ከምዝኾነ ቅዩድ መርትዖ ብ ሃንደበት ኣይተሰርዐን።
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
ምምሕልላፍ ጽሩይን ጽዑቕን ጸረ ኣካላት ብ ስርዓተ- ብይነት ካብ ኮቪድ-19 ዝሓወዩ ይፈሪ። ነዚ ዝደልዩ ከም ዘይክታበታዊ ኣገባብ ናይ ልኡም ዘይምጽያን ይፍለጡ።
This strategy was tried for SARS with inconclusive results.
እዚ መደባት ን SARS፡ ብዘየዕግብ ውጽኢት ተፈቲኑ ኢዩ።
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
ቫይራል ርግኡነት ማለት ኣካላትና ልኡም ጸረ-ነፍሳት ፈውስ ን SARS-CoV-2 ንምክልኻል ዝገብሮ ስራሕ ንጽበየሉ መገዲ ኢዩ።
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
ካልኦት መንገድታት ከም ኣብ ጸረ-ነፍስት ዝምርኮሱ cytotoxicity ከምኡ`ውን/ወይ phagocytosis ምጥቃም ውን ተኽእሎታት ኣሎ።